Stream
Stories
-
FDA requests public comments on ibogaine trial design
FDA is opening a docket to receive comments on design elements for early-phase trials of ibogaine drug products, with a deadline of November 20, 2026. The request follows guidance issued July 14, 2026 and seeks input on dose selection, safety monitoring, eligibility criteria and other protocol elements.
-
FDA issues priority review voucher for FAYUVI (rebisufligene etisparvovec-hopf)
The FDA announced that it has awarded a priority review voucher to the sponsor of FAYUVI, a gene therapy approved on September 17, 2026. The voucher is granted to Ultragenyx Pharmaceutical Inc. for this rare pediatric disease product that meets the criteria under the FD&C Act.
-
FDA determines pralidoxime chloride AUTOINJECTOR not withdrawn for safety or effectiveness
FDA has determined that pralidoxime chloride AUTOINJECTOR solution, 600 mg/2 mL (300 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination allows FDA to approve abbreviated new drug applications for the product if other requirements are met.
-
FDA classifies focused ultrasound system as class II
The Food and Drug Administration issued a final order classifying the focused ultrasound system for non-thermal, mechanical tissue ablation into class II with special controls, effective October 6, 2026. The order codifies the classification in 21 CFR 878.4405 and identifies the special controls that will provide reasonable assurance of safety and effectiveness.
-
FDA finalizes class II status for hyperoxia monitoring device adjunct to pulse oximetry
The FDA issued a final order on October 6, 2026, classifying the hyperoxia monitoring device adjunct to pulse oximetry into class II with special controls. The order, effective October 6, 2026, codifies the classification that was first applied on October 12, 2023.
-
FDA finalizes exemption for certain class II clinical toxicology test systems
The FDA issued a final order exempting specific class II clinical toxicology test systems from premarket notification (510(k)) requirements, effective October 6, 2026. This exemption will decrease regulatory burdens on the medical device industry and will eliminate private costs and expenditures required to comply with certain Federal regulations.
-
GL Pharm Tech Corporation registers Phase 3 trial of W2505 for erectile dysfunction
The study, first posted on ClinicalTrials.gov on October 5, 2026, plans to enroll 228 participants and begin in September 2026. It is a prospective, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of W2505.
-
Chiesi registers Phase 3 trial of CHF5993 vs Seretide in adolescent asthma
The study, first posted on ClinicalTrials.gov on October 5, 2026, plans to enroll 700 participants and start on November 16, 2026. It compares CHF5993 100/6/12.5 μg pMDI to Seretide Evohaler 125/25 μg pMDI over 52 weeks in adolescents with uncontrolled asthma.
-
FDA seeks public input to support ibogaine research
The FDA issued a request for information (RFI) to gather comments on early-phase clinical trial design for ibogaine drug products, including dose selection, safety monitoring and ethical oversight. Stakeholders have 45 days to submit comments, with the deadline on Friday, November 20, 2026.
-
Genmab registers Phase 3 trial of Rina-S in ovarian cancer
The study plans to enroll 602 participants and is expected to start in November 2026. It compares Rina-S alone or in combination with an approved standard of care treatment against the same available standard of care therapy by itself, or no treatment.
-
Incyte posts results of Phase 3 axatilimab trial in chronic graft-versus-host disease
Results for the Phase 3, open-label study of axatilimab in Japanese participants with recurrent or refractory active chronic graft-versus-host disease were first posted on ClinicalTrials.gov on October 5, 2026. The study enrolled 21 participants and completed primary data collection on August 6, 2025.
-
Intra-Cellular Therapies, Inc. posts results of Lumateperone schizophrenia relapse study
The Phase 3 study enrolled 592 participants and was completed with primary completion on July 25, 2024. Results were first posted on ClinicalTrials.gov on October 5, 2026.